MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG

Martín, C. (Universidad de Zaragoza) ; Marinova, D. ; Aguiló, N. (Universidad de Zaragoza) ; Gonzalo-Asensio, J. (Universidad de Zaragoza)

Resumen: At its 100th birthday of its first administration to a newborn, BCG has been (and continues being) an inspiration for the construction and development of hundreds of new TB vaccine candidates in the last two and a half decades. Today, 14 candidates are in clinical development inside the global TB vaccine pipeline. MTBVAC is one of these candidates. Based on a live-attenuated Mycobacterium tuberculosis clinical isolate, MTBVAC''s 25 years of vaccine discovery, construction and characterisation have followed Pasteur principles, and in the process, BCG has served as a reference gold standard for establishing the safety and protective efficacy of new TB vaccine candidates. MTBVAC, which contains the antigen repertoire of M. tuberculosis, is now poised to initiate Phase 3 efficacy trials in newborns in TB-endemic countries. BCG''s efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life. Today, WHO recognises the importance that any new TB vaccine designed for administration at birth, should show similar non-specific benefits as BCG vía mechanisms of trained immunity and/or cross-reactivity of adaptive immune responses to other pathogens. Key recent studies provide strong support for MTBVAC''s ability of inducing trained immunity and conferring non-specific heterologous protection similar to BCG. Research on alternative delivery routes of MTBVAC, such as a clinically feasible aerosol route, could facilitate vaccine administration for long-term TB eradication programmes in the future. © 2021 The Author(s)

Idioma: Inglés

DOI: 10.1016/j.vaccine.2021.06.049

Año: 2021

Publicado en: VACCINE 39, 50 (2021), 7277-7285
ISSN: 0264-410X

Factor impacto JCR: 4.169 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 73 / 140 = 0.521 (2021) - Q3 - T2
Categ. JCR: IMMUNOLOGY rank: 94 / 163 = 0.577 (2021) - Q3 - T2

Factor impacto CITESCORE: 6.7 - Medicine (Q1) - Veterinary (Q1) - Immunology and Microbiology (Q2) - Biochemistry, Genetics and Molecular Biology (Q2)

Factor impacto SCIMAGO: 1.392 - Immunology and Microbiology (miscellaneous) (Q1) - Veterinary (miscellaneous) (Q1) - Public Health, Environmental and Occupational Health (Q1) - Infectious Diseases (Q1)

Financiación: info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
Financiación: info:eu-repo/grantAgreement/ES/MICINN/RTC-2017-6379-1

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)